Shire says ProAmatine remains available to patients
Biopharmaceutical company Shire plc, Wednesday providing an update on the approval status and availability of ProAmatine, said ProAmatine remains available to patients as discussions between FDA and the company continue regarding its New Drug Application.
Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study of its lead product, dalbavancin, a long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.